Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Spreadex-Sporting Index deal created a monopoly, says CMA

(Sharecast News) - Spreadex's acquisition of Sporting Index came under fire on Friday, after the UK competition watchdog ruled the deal had created a monopoly. The Competition and Markets Authority said the tie-up could lead to a worse user experience, a more limited range of products and/or higher prices for British consumers.

As a result, it wants Spreadex to agree to offload the business, otherwise it will impose an order requiring its sale to a CMA-approved buyer.

A Spreadex spokesman told Reuters: "Spreadex strongly disagrees with this entirely disproportionate decision and are reviewing all available options."

Spreadex acquired the rival spread betting firm from French lottery operator FDJ in 2023 for an undisclosed sum.

Following an initial probe, the CMA concluded in 2024 that the tie-up would likely "substantially lessen" competition. Spreadex appealed to the Competition Appeal Tribunal, however, which in turn referred the decision back to the CMA for reconsideration in March this year.

The CMA said that since then it had obtained further evidence, which had led it to conclude a monopoly had been created.

Richard Feasey, chair of the independent panel reviewing the merger, said: "We found that the merger substantially lessens competition by removing Spreadex's only competition in the sports spread betting market in the UK.

"We also found that the only effective remedy would be for Spreadex to sell Sporting Index, to restore competition."

Privately-owned Spreadex was founded in 1999 by former City trader Jonathan Hufford.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.